News › Industry News, News

Eli Lilly Sues Four Telehealth Sites Selling Compounded Versions of Zepbound, Mounjaro

April 24, 2025

Eli Lilly is suing four telehealth companies for allegedly selling compounded copies of the manufacturer’s tirzepatide weight loss drugs, Zepbound and Monjaro. The lawsuits filed Wednesday accuse the telehealth sites of deceiving consumers about “untested, unapproved drugs” and turning them away from Lilly’s name-brand medicines.

Complaints include allegations of switching patients to compounded medication with different additives or at different dosages than those offered by Lilly, and allegations of selling in untested forms (pills) that have not been approved by the FDA. One complaint addresses a false claim of having developed the first “cosmetic” GLP-1, a distinction not recognized by the FDA for tirzepatide.

Read more at NPR >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
    • MedSafe Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics